The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.
Avastin's approval in HER2-negative metastatic breast cancer was revoked in the US (and Canada) recently, a decision at odds with...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

